Journal News

MCP: When mitochondria make B cells go bad

John Arnst
Feb. 1, 2018

B-cell chronic lymphocytic leukemia, or B-CLL, is the most common type of leukemia in adults and primarily affects elderly patients. The disease results from a patient’s bone marrow overproducing immature lymphocytes, a form of white blood cells that fight infections less effectively than their healthy counterparts but survive longer, ultimately overwhelming them and spreading unchecked. Unlike acute leukemia, B-CLL can take several years to cause problems for a patient, but it is less responsive to chemotherapy.

When mitochondria, highlighted here in cow cells, suffer age-related oxidative damage, they can give rise to chronic lymphocytic leukemia.courtesy of Torsten Wittmann, University of California, San Francisco

While novel treatments have been developed in recent years, they only target the B cells once they’ve mutated to an immature, cancerous state. To develop treatments for B-CLL that might prevent B cells from becoming cancerous in the first place, researchers led by Christopher Gerner at the University of Vienna and Vienna Metabolomics Center have performed a comprehensive proteomics analysis of B-CLL cells and mature B cells in young and elderly patients. They described their work in a paper in the journal Molecular & Cellular Proteomics.

“It could be nice to not only target the cancer cells, but those cells prone to becoming cancer cells,” Gerner said. “What we actually saw when we compared the young and the elderly donors was a very clear signature of mitochondrial stress and metabolic stress.”

Gerner and colleagues found that B-CLL cells have an increased expression of stem cell-associated molecules and a reduced expression of tumor-suppressing molecules and stress-related serotonin transporters as well as an observed increase in glutamine consumption and beta-oxidation of fatty acid.

This indicated that reactive oxidative species, which are carcinogenic and cause damage to cells, were being upregulated, Gerner said, which would explain why the incidence of mutations that lead to B-CLL increases with age. The researchers hope that the alterations in regulation also may provide a proteomic signature for immunosenescence, the immune system’s natural weakening with age.

Gerner and his fellow researchers plan to continue this research by performing their proteomic analysis on blood samples taken from greater numbers of healthy elderly people and B-CLL patients to ultimatelybe able to test when mitochondria have become predisposed for the disease.

“The pressure on those cells was simply different … and this pressure is something I would like to detect and measure in patients,” Gerner said. “That would be the ultimate aim.”

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
John Arnst

John Arnst was a science writer for ASBMB Today.

Related articles

From the journals: MCP
Nuala Del Piccolo
From the journals: MCP
Laura Elyse McCormick
From the journals: MCP
Courtney Chandler
From the journals: MCP
Inayah Entzminger
From the journals: MCP
Nuala Del Piccolo & Laurel Oldach

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Living in a bubble
Annual Meeting

Living in a bubble

Sept. 29, 2022

This symposium, Protein Machines and Disorder, will be part of #DiscoverBMB 2023.

Keep your friends close and your RNAs closer
Annual Meeting

Keep your friends close and your RNAs closer

Sept. 29, 2022

This symposium, Regulation of RNA, will be part of #DiscoverBMB 2023.

A membrane ATPase without transporter activity
Journal News

A membrane ATPase without transporter activity

Sept. 28, 2022

A classic article in the Journal of Biological Chemistry reflects on Guido Guidotti’s laboratory and the search for CD39.

The era of “smart” organelles
Annual Meeting

The era of “smart” organelles

Sept. 28, 2022

This symposium, Organelles, Mechanisms and Phase Properties of Cellular Quality Control, will be part of #DiscoverBMB 2023.

Lipids, lipids everywhere!
Annual Meeting

Lipids, lipids everywhere!

Sept. 27, 2022

This symposium, Lipid Dynamics and Signals in Membrane and Protein Structure, will be part of #DiscoverBMB 2023.

A target to prevent kidney injury by chemotherapy
Journal News

A target to prevent kidney injury by chemotherapy

Sept. 27, 2022

“Many people don’t realize that the side effects of chemotherapy are not limited to hair loss, diarrhea and nausea.”